Last reviewed · How we verify
DB289
At a glance
| Generic name | DB289 |
|---|---|
| Also known as | pafuramidine maleate |
| Sponsor | Immtech Pharmaceuticals, Inc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP) (PHASE3)
- Randomized, Double-Blind Phase 1 Safety and Tolerability Study of Pafuramidine Maleate (DB289) in Healthy Subjects (PHASE1)
- Trial of DB289 for the Treatment of Stage I African Trypanosomiasis (PHASE2)
- A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis (PHASE2)
- Prophylactic Antimalarial Activity of DB289 in Volunteers (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DB289 CI brief — competitive landscape report
- DB289 updates RSS · CI watch RSS
- Immtech Pharmaceuticals, Inc portfolio CI